Alkem Labs Completes Trade Generics Business Transfer for ₹532.5 Crores
Alkem Laboratories has successfully completed the transfer of its trade generics business to wholly-owned subsidiary Alkem Wellness Limited for a total consideration of ₹532.5 crores. The final payment of ₹32.5 crores was made on December 30, 2025, completing the slump sale transaction that became effective from October 1, 2025, as part of the company's strategic business restructuring initiative.
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories Limited , a prominent player in the Indian pharmaceutical industry, has completed the transfer of its Trade Generics Business to its wholly-owned subsidiary, Alkem Wellness Limited, with a total consideration of ₹532.5 crores.
Business Transfer Completion
On December 30, 2025, the company announced the completion of the business transfer with the final payment of ₹32.5 crores from Alkem Wellness to the parent company. This brings the aggregate sale consideration to ₹532.5 crores under the Business Transfer Agreement.
| Transaction Details: | Amount/Date |
|---|---|
| Final Payment: | ₹32.5 crores |
| Total Consideration: | ₹532.5 crores |
| Payment Date: | December 30, 2025 |
| Effective Transfer Date: | October 1, 2025 |
Timeline of Events
The strategic restructuring process began with the initial intimation to stock exchanges on December 10, 2024. The Business Transfer Agreement was formally executed on September 26, 2025, setting October 1, 2025, as the effective date for the business transfer on a slump sale basis.
| Key Milestones: | Date |
|---|---|
| Initial Intimation: | December 10, 2024 |
| Agreement Execution: | September 26, 2025 |
| Transfer Effective Date: | October 1, 2025 |
| Final Payment: | December 30, 2025 |
Regulatory Compliance
The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Manish Narang signed the regulatory filing, ensuring transparency for investors and stakeholders.
Strategic Impact
This restructuring move represents a significant step in streamlining Alkem Laboratories' operations. By transferring the Trade Generics Business to Alkem Wellness as a going concern, the company has created a more focused operational structure that could enhance resource allocation and operational efficiency across its business segments.
The completion of this ₹532.5 crore transaction marks a milestone in the company's strategic reorganization efforts, positioning both entities for optimized performance in their respective operational areas.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.86% | +1.11% | +3.19% | -3.49% | -3.75% | +33.25% |
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
